Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$66.03 +0.7%	$64.57	$52.50 ▼ $77.00	$1.42B	0.55	312,628 shs	179,572 shs
BEAM Beam Therapeutics	$16.71 -0.3%	$17.69	$13.53 ▼ $35.25	$1.69B	2.09	1.48 million shs	1.34 million shs
KNSA Kiniksa Pharmaceuticals International	$28.72 +1.0%	$26.15	$17.38 ▼ $30.69	$2.08B	0.06	517,003 shs	701,134 shs
NWBO Northwest Biotherapeutics	$0.26 -0.8%	$0.28	$0.17 ▼ $0.50	$378.31M	-1.09	1.94 million shs	2.21 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	+0.72%	+2.71%	+14.26%	-0.45%	+12.81%
BEAM Beam Therapeutics	-0.30%	+0.54%	-0.71%	-28.04%	-27.16%
KNSA Kiniksa Pharmaceuticals International	+0.98%	+1.09%	+6.81%	+23.85%	+54.33%
NWBO Northwest Biotherapeutics	-0.77%	-3.52%	-6.72%	+9.74%	-43.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIP ANI Pharmaceuticals	3.4923 of 5 stars	2.5	1.0	3.3	1.5	3.3	1.3
BEAM Beam Therapeutics	2.952 of 5 stars	4.5	1.0	0.0	1.5	2.5	0.6
KNSA Kiniksa Pharmaceuticals International	3.2109 of 5 stars	3.5	3.0	0.0	2.6	3.3	0.6
NWBO Northwest Biotherapeutics	0.1116 of 5 stars	0.0	2.0	0.0	2.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	3.00	Buy	$80.13	21.35% Upside
BEAM Beam Therapeutics	3.00	Buy	$48.75	191.74% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$38.80	35.10% Upside
NWBO Northwest Biotherapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NWBO, KNSA, ANIP, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$86.00 ➝ $86.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
4/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/21/2025	ANIP ANI Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$62.00 ➝ $65.00
4/16/2025	KNSA Kiniksa Pharmaceuticals International	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$34.00 ➝ $34.00
4/11/2025	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$86.00 ➝ $86.00
4/7/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/28/2025	BEAM Beam Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$42.00 ➝ $42.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$614.38M	2.33	$7.65 per share	8.63	$19.11 per share	3.46
BEAM Beam Therapeutics	$63.52M	26.45	N/A	N/A	$8.86 per share	1.89
KNSA Kiniksa Pharmaceuticals International	$481.17M	4.36	N/A	N/A	$6.60 per share	4.35
NWBO Northwest Biotherapeutics	$1.38M	272.03	N/A	N/A	($0.07) per share	-3.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	-$18.52M	-$1.27	N/A	15.68	N/A	-3.12%	21.35%	7.52%	8/5/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	N/A	114.88	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)
NWBO Northwest Biotherapeutics	-$83.78M	-$0.07	N/A	∞	N/A	-5,757.57%	N/A	-303.49%	8/7/2025 (Estimated)

Latest NWBO, KNSA, ANIP, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/22/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.08	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	NWBO Northwest Biotherapeutics	N/A	-$0.01	N/A	-$0.01	N/A	$0.38 million
5/9/2025	Q1 2025	ANIP ANI Pharmaceuticals	$1.37	$1.70	+$0.33	$0.69	$179.75 million	$197.12 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million
3/31/2025	Q4 2024	NWBO Northwest Biotherapeutics	N/A	-$0.02	N/A	-$0.02	N/A	$0.23 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
NWBO Northwest Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	1.46	2.66	1.98
BEAM Beam Therapeutics	N/A	8.81	8.81
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43
NWBO Northwest Biotherapeutics	N/A	0.06	0.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
BEAM Beam Therapeutics	99.68%
KNSA Kiniksa Pharmaceuticals International	53.95%
NWBO Northwest Biotherapeutics	0.04%

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	12.70%
BEAM Beam Therapeutics	3.50%
KNSA Kiniksa Pharmaceuticals International	53.48%
NWBO Northwest Biotherapeutics	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	600	21.66 million	18.91 million	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
NWBO Northwest Biotherapeutics	20	1.46 billion	1.33 billion	Not Optionable

NWBO, KNSA, ANIP, and BEAM Headlines

Recent News About These Companies

Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Pass Below 200 Day Moving Average - Here's Why

June 17, 2025 | marketbeat.com

Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments

June 13, 2025 | finanznachrichten.de

Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments

June 11, 2025 | prnewswire.com

Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Pass Below 200-Day Moving Average - Time to Sell?

June 7, 2025 | marketbeat.com

Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?

May 31, 2025 | marketbeat.com

Northwest Biotherapeutics: A Spike On Their Expected Imminent Approval

April 22, 2025 | seekingalpha.com

Citadel Securities, Virtu Must Face Biotech Stock Spoof Suit (1)

March 29, 2025 | news.bloomberglaw.com

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments

January 13, 2025 | msn.com

Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing

December 26, 2024 | prnewswire.com

Northwest Biotherapeutics: All Is Not Well With This One

December 14, 2024 | seekingalpha.com

Behind the Bell: Arcutis Biotherapeutics

November 5, 2024 | nasdaq.com

Northwest Registered Agent Review 2024: Features, Pricing & More

October 24, 2024 | forbes.com

0K95.IL,0P0000AFQ5,0 (0K95.IL)

September 14, 2024 | nz.finance.yahoo.com

Traders News Digs into the Biotech Space and Releases New Feature Profile

August 15, 2024 | br.advfn.com

Northwest Biotherapeutics addresses rumors and market activity

August 4, 2024 | uk.investing.com

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities

July 3, 2024 | prnewswire.com

Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property

June 17, 2024 | prnewswire.com

Northwest Biotherapeutics Inc (NWBO) Dividend History

May 25, 2024 | nasdaq.com

Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors

March 21, 2024 | prnewswire.com

‘Spoofing’ case might draw back curtain on high-speed trading firms

March 2, 2024 | ft.com

Northwest Biotherapeutics, Inc. (NWBO)

February 29, 2024 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NWBO, KNSA, ANIP, and BEAM Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

$66.03 +0.47 (+0.72%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$66.03 0.00 (-0.01%)

As of 06/23/2025 05:06 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Beam Therapeutics NASDAQ:BEAM

$16.71 -0.05 (-0.30%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$17.06 +0.34 (+2.06%)

As of 07:02 AM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.72 +0.28 (+0.98%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$28.71 -0.01 (-0.03%)

As of 06/23/2025 04:10 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Northwest Biotherapeutics OTCMKTS:NWBO

$0.26 0.00 (-0.77%)

As of 06/23/2025 03:57 PM Eastern

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time